China Biomedical Innovations Conference 2009 focuses on Anti-infection, Anti-cancer and Stem Cell Biology Innovation and Collaboration

5 – 6 November 2009, Ramada Plaza Pudong Shanghai, China

Shanghai, China (July 27, 2009) /ChinaNewswire.com/ — China Biomedical Innovations Conference 2009, co-organized by Shanghai Pharmaceutical Profession Association (SPPA), Shanghai Society for Biotechnology (SSBT), The Institutes of Biomedical Sciences (IBS), Fudan University, The Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine, and Tongji University Medical School will be held on 5 – 6 November 2009 in Ramada Plaza Pudong Shanghai, China. This event will feature a thriving conference program, incorporating intensive onsite demonstration, dedicated anti-cancer & stem cell biology workshop and interactive business partnership salon.

Upon the establishment and improvement of China Drug Supervision and Administration System, the global biomedical industry value chain has been shifting towards the biotech industry zones in China. The fastest-growing biomedical market portfolio in China is expected to be dominated by monoclonal antibody, gene therapeutics and vaccines for anti-infection and anti-cancer diagnostics and therapeutics. From a long-term sustainable perspective, it is highly suggested that the issues on how to strategically capture and leverage the emerging opportunities in anti-cancer and anti-infection diagnostics and therapeutics be well illustrated on such a platform.

Over 40 distinguished world-class speakers will present the conference on behalf of Chinese Center for Disease Control and Prevention, Shanghai Society for Biotechnology, Shanghai Pharmaceutical Professional Association, Development Center for Biotechnology (DCB, Taiwan), EU Biovalley, German Cancer Research Center, Medicon Valley, Japan Bioindustry Association, Shanghai Food & Drug Municipal Administration, Shanghai Jiao Tong University School of Medicine, Sanofi-Pastur, Novartis, Biogen Idec, AstraZeneca, GlaxoSmithKline, GE Healthcare, Roche, Merck & Co. In., Pfizer, Johnson & Johnson, Boehringer Ingelheim, Onyx Pharmaceuticals, Enzon Pharmaceuticals, Bristol-Myers Squibb, Covance, Celltrion, Qiagen, Millipore, Invitrogen and so forth.

Event Features:
200+ Distinguished Attendees
80+ Biotechnology and Biopharma Companies
50+ Media Partners of Marketing Support with eNewsletter every two weeks
40+ World-class Speakers and Panelists
30+ Biotechnology and Biomedical Technology R&D Institutions
25+ Countries and Regions Represented
20+ Professional Journalists
15+ Strategic Event Partners
5 Specialized Sessions
1 Unparalleled Networking Opportunity

Matchmaking and Networking:
Onsite SMS Platform for real-time interactions between speakers and audience
Onsite SMS Platform for attendees' initiated one-to-one meeting assistance
Participant Message Board as an alternative onsite communication medium

It is a therefore must attend event for high-level decision makers from biotechnology/biopharmaceutical corporations, biopharmaceutical and biomedical technology R&D institutions, new drug clinical research hospitals, NGOs, biomedical diagnostic companies, pre-clinical & clinical trial laboratories, biomedical facilities and equipment manufacturers or service suppliers, biotechnology transfer agencies and financial & investing institutions, etc.

On behalf of the Organizing Committee, we are pleased to invite you to attend China Biomedical Innovations Conference 2009 on 5-6 November 2009 in Shanghai, China.

For more information, please contact: lifescience@igvision.com; Or visit conference official website: www.biochinaforum.com